Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5265-5272

  Nagata, Yoshika ^a   Hanagiri, Takeshi ^a   Takenoyama, Mitsuhiro ^a   Fukuyama, Takashi ^a   Mizukami, Makiko ^a   So, Tetsuya ^a   Ichiki, Yoshinobu ^a   Sugaya, Masakazu ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HLA CW 0702 ANTIGEN; PHYTOHEMAGGLUTININ; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CELL ISOLATION; CELL SPECIFICITY; CELL TRANSFORMATION; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; DNA, COMPLEMENTARY; HLA-C ANTIGENS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 22344450200     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2542     Document Type: Article

References (42)

1. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001;71:1759-64.
2. Ohe Y, Ishizuka N, Tamura T, et al. Japan Clinical Oncology Group. Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotharapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci 2003;94: 729-34.
3. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:16438.
4. van der Eruggen P, Szikora JP, Boel P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol 1994;24:2134-40.
5. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autobgous cytolytic T lymphocytes. J Exp Med 1994;179:921-30.
6. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2: 167-75.
7. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T, A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182: 689-98.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4: 321-7.
9. Godelaine D, Carrasco J, Lucas S, et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 2003;171:4893-7.
10. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freunds adjuvant in patients with resected high-risk melanoma. J Immunother 1999;22:431-40.
11. Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor associated antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001;98:10290-5.
12. Lee KH, Wang E, Nielsen ME, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292-300.
13. Sugaya M, Takenoyama M, Osaki T, et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002;122:282-8.
14. Takenoyama M, Yoshino I, Fujie H, et al. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res 1998;89:60-6.
15. So T, Takenoyama M, Sugaya M, et al. Generation of autologous tumor-specific T cell clones from a patient with adenosquamous carcinoma of the lung. Jpn J Clin Oncol 2001;31:311-7.
16. Takenoyama M, Yoshino I, Eifuku R, et al. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 2001;92:309-15.
17. Herin M, Lemoine C, Weynants P, et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 1987;39: 390-6.
18. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
19. Hansen ME, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203-10.
20. Falk K, Rotzschke O, Grahovac E, et al. Allele-specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci U S A 1993;90:12005-9.
21. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
22. Ichiki Y, Takenoyama M, Mizukami M, et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004;172:4844-50.
23. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
24. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
25. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
26. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
27. Bobbins PF, El-Gamil M, Li YF, et al. A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
28. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 1995;92:7976-80.
29. Coulie PG, Weynants P, Lehmann F, et al. Genes coding for tumor antigens recognized by human cytolytic T lymphocytes. J Immunother 1993;14: 104-9.
30. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63:6076-83.
31. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the α-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001;61:4078-83.
32. Slingluff CL Jr, Cox AL, Stover JM Jr, Moore MM, Hunt DF, Engelhard VH. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994;54: 2731 -7.
33. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004;16:76-81.
34. Gileadi U, Moins-Teisserenc HT, Correa I, et al. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J Immunol 1999;63: 6045-52.
35. Schultz ES, Chapiro J, Lurquin C, et al. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med 2002;195:391-9.
36. Robbins PF, El-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanomaspecific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
37. Engelhard VH. Creating new peptide antigens by slicing and splicing proteins. Nat Immunol 2004;5: 128-9.
38. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004;427: 252-6.
39. Yasuda M, Takenoyama M, Obata Y, et al. Tumor-in-filtrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer. Cancer Res 2002;62:1751-6.
40. Heidecker L, Brasseur F, Probst-Kepper M, Gueguen M, Boon T, Van den Eynde BJ. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol 2000;164:6041-5.
41. Marsh GES, Parham PP, Barber DL. Cw*07-Cw7, In: The HLA facts book. New York: Academic Press: 2000. p. 257.
42. Tokunaga K, Ishikawa Y, Ogawa A, et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997;46:199-205.